Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
her2-siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral, Intravenous
01
Overview
HER2 siRNA (siHER2) is a small interfering RNA (siRNA) designed to target and silence the expression of human epidermal growth factor receptor 2 (HER2/ErbB2) at the mRNA level. Unlike monoclonal antibodies (such as trastuzumab) or small molecule tyrosine kinase inhibitors (such as lapatinib) which block HER2 protein activity, HER2 siRNA halts the synthesis of the HER2 protein itself. This approach has been shown to overcome both intrinsic and acquired resistance to traditional HER2-targeted therapies in HER2-positive breast cancer and other HER2-overexpressing malignancies. Various delivery systems, including polymer-modified mesoporous silica nanoparticles (such as those developed by PDX Pharmaceuticals), are being investigated to enable effective systemic delivery of HER2 siRNA to solid tumors.
- Other names
- ErbB2 siRNAErbB-2 siRNAErbB 2 siRNAHER2 siRNAHER-2 siRNAHER 2 siRNAsiHER2siHER-2siHER 2
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on her2-siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on her2-siRNA.